| 摘要 |
<p>There is disclosed a method for selectively inhibiting interleukin-2 (IL-2) signal transduction that results in immunosuppressive activity useful for treatment of graft versus host disease, autoimmune diseases, certain T-cell or B-cell leukemias and lymphomas, and for transplant recipients, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of myristylated phosphatidic acid (myrPA) which occurs in response to IL-2 signaling.</p> |
